Press Release AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants Aug 13
Press Release Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Aug 12
Press Release Mobilewalla and SPACSphere Acquisition Corp. Announce Filing of Registration Statement on Form S-4 Regarding Proposed Business Combination Aug 12